Sonoma Pharmaceuticals Files 8-K

TL;DR

Sonoma Pharma filed an 8-K on 9/20/24, check for updates.

AI Summary

Sonoma Pharmaceuticals, Inc. filed an 8-K on September 20, 2024, reporting on other events and financial statements. The company, formerly known as Oculus Innovative Sciences, Inc., is incorporated in Delaware and headquartered in Boulder, Colorado.

Why It Matters

This filing provides updates on the company's corporate events and financial reporting, which are crucial for investors to understand the company's current status and regulatory compliance.

Risk Assessment

Risk Level: low — This is a routine filing reporting on corporate events and financial statements, not indicating any immediate significant risks.

Key Players & Entities

• Sonoma Pharmaceuticals, Inc. (company) — Registrant
• Oculus Innovative Sciences, Inc. (company) — Former company name
• September 20, 2024 (date) — Date of earliest event reported
• Delaware (jurisdiction) — State of incorporation
• Boulder, CO (location) — Principal executive offices location

FAQ

Key Financial Figures

• $0.0001 — principal, shares of its common stock, $0.0001 par value per share. On March 8, 2024,

Filing Documents

• sonoma_8k.htm (8-K) — 31KB
• sonoma_ex0501.htm (EX-5.1) — 9KB
• image_004.jpg (GRAPHIC) — 3KB
• 0001683168-24-006556.txt ( ) — 219KB
• snoa-20240920.xsd (EX-101.SCH) — 3KB
• snoa-20240920_lab.xml (EX-101.LAB) — 33KB
• snoa-20240920_pre.xml (EX-101.PRE) — 24KB
• sonoma_8k_htm.xml (XML) — 4KB

01

Item 8.01 Other Events. As previously disclosed, on December 15, 2023, Sonoma Pharmaceuticals, Inc. (the "Company") entered into an Equity Distribution Agreement (the "Agreement") with Maxim Group LLC ("Maxim"), pursuant to which the Company may offer and sell, from time to time, through Maxim, as sales agent or principal, shares of its common stock, $0.0001 par value per share. On March 8, 2024, the Company entered into an amendment to the Agreement ("Amendment No. 1"). Sales of shares of common stock under the Agreement, as amended by Amendment No. 1, will be made pursuant to the registration statement on Form S-3 (File No. 333-275311), which was declared effective by the U.S. Securities and Exchange Commission (the "SEC") on November 20, 2023, the prospects included therein, and a related prospectus supplement filed with the SEC on September 20, 2024. The foregoing summary of the Agreement and Amendment No. 1 does not purport to be complete and is qualified in its entirety by reference to the full text of the Agreement and Amendment No. 1, which are filed as Exhibit 1.1 to the Company's Current Report on Form 8-K filed on December 18, 2023 and Exhibit 1.1 to the Company's Current Report on Form 8-K filed on March 8, 2024, respectively. The opinion of Polsinelli PC regarding the validity of the shares of common stock that will be issued pursuant to the Agreement, as amended by Amendment No. 1, is filed herewith as Exhibit 5.1. This Current Report on Form 8-K shall not constitute an offer to sell or the solicitation of an offer to buy any shares under the Agreement, as amended by Amendment No. 1, nor shall there be any sale of such shares in any state in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state.

Financial Statements and Exhibits

Financial Statements and Exhibits. (d) Exhibits . Exhibit Number Description 1.1 Equity Distribution Agreement, by and between Sonoma Pharmaceuticals, Inc. and Maxim Group LLC, dated December 15, 2023 (included as Exhibit 1.1 to the Company's Current Report on Form 8-K filed on December 18, 2023, and incorporated herein by reference). 1.2 Amendment No. 1 to Equity Distribution Agreement, by and between Sonoma Pharmaceuticals, Inc. and Maxim Group LLC, dated March 8, 2024 (included as Exhibit 1.1 to the Company's Current Report on Form 8-K filed on March 8, 2024, and incorporated herein by reference). 5.1* Opinion of Polsinelli PC 23.1 Consent of Polsinelli PC (included in Exhibit 5.1 ). 104 Cover Page Interactive Data File (formatted in Inline XBRL in Exhibit 101). * Filed herewith. 2

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. SONOMA PHARMACEUTICALS, INC. Date: September 20, 2024 By: /s/ Amy Trombly Name: Title: Amy Trombly Chief Executive Officer 3

View Full Filing

View this 8-K filing on SEC EDGAR